Background. Haemodialysis (HD) and peritoneal dialysis (PD) should be regarded as complementary methods of renal replacement therapy. Approximately 10-20% of patients on PD are transferred annually to HD due to technique failure. Much smaller proportion of patients changes modality from HD to PD, predominantly due to vascular access problems, cardiac disease or patient preference. The effects of these transfers on therapy outcome, patient and technique survival have not been studied, with research focusing on outcome measures within the single modality and comparisons between the two methods. Methods. We have analysed retrospectively a cohort of 264 patients treated with PD in a single PD centre during 1994-2006. Patient characteristics, therapy measures and outcome of patients were compared between patients for whom PD was the initial method of renal replacement therapy (group 1, n = 197) and those transferred to PD from haemodialysis because of complications (group 2, n = 67). The Kaplan-Meier method and Cox proportional hazards multiple regression analysis were used to assess patient and technique survival. Results. In patients transferred from HD, significantly less had diabetes (11.9% versus 38.1%, P < 0.0001) and there were also significantly more females (57% versus 42.2%, P < 0.05). Baseline Kt/V was significantly higher in the primary PD therapy group (2.46 ± 0.57 versus 2.11 ± 0.48, P < 0.001), due to lower residual renal function in patients transferred from HD. Group 2 had also significantly higher peritonitis rate (0.86 versus 0.62 episode/year, P < 0.05). During the time of observation, 71 patients have died, in 100 patients kidney transplantation was performed, 56 were transferred to HD, renal function recovered in 5 and 32 were still on PD at the end of the study. No significant differences were observed in unadjusted patient survival, but technique survival was significantly lower in group 2 (P < 0.05). In the Cox multiple regression model, diabetes status, age and albumin level significantly influenced survival. Relative risk of death was not increased significantly in patients transferred from HD. Conclusions. Our data suggest that outcome of patients transferred from HD is similar to that achieved in patients in whom PD is the first choice therapy. Thus, this option should be strongly considered in patients experiencing complications on HD, mainly vascular access problems, heart failure or intradialytic hypotension.
Introduction
Patients with chronic kidney diseases should be timely incorporated into educational programmes to allow optimal choice of a dialysis method based on medical indications and contraindications, as well as patient preference. In the concept of integrated care, haemodialysis (HD) and peritoneal dialysis (PD) are regarded as complementary methods of renal replacement therapy and these two modalities should be used to achieve best patients' outcomes [1, 2] . While survival of patients appears to be equivalent in the two methods, PD technique survival is often unsatisfactory with as many as 10-20% of PD patients being transferred annually to HD due to technique failure [3] . This limitation of PD is well recognized, and peritonitis, catheter problems, ultrafiltration failure and loss of patient independence to perform dialysis are the most common causes of transfer to HD [4] [5] [6] . A much smaller proportion of patients change modality from HD to PD, predominantly due to vascular access problems, cardiac disease or patient preference. The causes of these transfers and their effects on therapy outcome have not been studied, with research focusing rather on outcome measures within the single modality and comparisons between these two methods. However, in many PD programmes, a significant percentage of patients, ranging from 15 to 25%, has been transferred from HD 2890 T. Liberek et al. due to problems experienced during this therapy or patient choice [3, 7, 8] . Surprisingly, little is known about causes of these transfers and therapy outcome in this group of patients, and often the idea of transferring HD patients to PD due to complications appears to be controversial, especially among nephrologists who are less experienced with PD.
Therefore, the aim of this study was to analyse and compare patient characteristics, therapy measures and outcome between patients transferred from HD and those for whom PD was the first modality in a large cohort of patients treated in a single centre.
Patients and methods
We have analysed retrospectively a cohort of 257 patients who had started therapy with PD in the Department of Nephrology, Transplantology and Internal Medicine of the Medical University of Gdańsk, during years 1994-2005. The patients were followed up from the start of PD therapy until 31 December 2006. No patients treated during that time were excluded from the analysis and no patients were lost to follow-up. As seven PD patients entered the therapy for the second time after a failed transplant, 264 separate PD 'careers' were analysed.
Therapy measures, patient characteristics and outcomes of patients were compared between patients transferred from HD and those for whom PD was the first modality. Patients 'transferred from HD' were defined as these who have been treated with HD for at least 3 consecutive months, and HD had been chosen initially as a long-term therapy. Subsequently, this therapy has been changed to PD because of complications or patient preference. Patients who were treated temporarily with the use of central vein catheters in a bridge-in period before starting PD as a planned long-term therapy were not included in this group. Patient comorbidity was assessed according to Charlson et al. [9] . All the clinical and laboratory parameters used in the survival analysis were evaluated before the start of PD. The peritoneal equilibration test and clearance studies were performed shortly (usually 2-4 months) after the initiation of PD therapy. The Watson formula [10] was used to estimate total body water in the Kt/V calculations and the Du Bois equation [11] for calculation of body surface area for normalizing creatinine clearance. Residual renal creatinine clearance was calculated as an average of creatinine and urea clearances.
Statistical analysis
Variables with normal distribution were compared between groups using Student's t-test and the Mann-Whitney test was used for variables without normal distribution. The chi-square test was used to compare categorical variables. Survival analysis was performed with the Kaplan-Meier method, and unadjusted survival was compared with the log-rank test. Cox proportional hazards multiple regression analysis was used to correct for case-mix, the presence of comorbid conditions and other factors. In patient survival analysis, only death was considered as a final event and patients were censored at transplantation, transfer to HD, recovery of renal function or at the end of the observation period. In the technique survival analysis, permanent transfer to HD was a final event and patients were censored at other events, including death. Short-term treatment switch to HD following catheter removal due to peritonitis or other technical problems with a subsequent return to PD was ignored in the analysis. In the combined patient and technique survival (which described patient alive and treated with peritoneal dialysis), both death and transfer to HD were considered as final events and patients were censored at transplantation, recovery of renal function and at the end of the study.
Data were expressed as the mean ± standard deviation, and median and range were used for non-normally distributed variables. The P-value of < 0.05 was interpreted as statistically significant. Statistical analyses were performed with the software package STATISTICA (StatSoft, Inc., 2007, Tulsa, OK, USA).
Results
At the start of PD, mean age of all patients was 51.4 ± 15.1 years. Eighty-seven patients (32.9%) were older than 60 years. Diabetes was diagnosed in 83 patients (31.4%) and diabetic nephropathy was considered to be the cause of chronic renal failure in 75 patients (28.4%). For 197 patients, PD was the initial method of renal replacement therapy (Group 1), and 67 (25.4%) patients had been transferred to PD from haemodialysis (Group 2). In majority of them (43 patients, 64%), therapy was changed because of vascular access problems, in 14 (21%) due to heart failure or severe intradialytic hypotension and in 10 (15%) due to patient preference. The median time on HD before transfer to PD was 18 months (range 3-268 months). Patient characteristics of the two groups are given in Table 1 . In group 2, significantly less patients had diabetes, it also included significantly more females than group 1. There was a small but significant difference in body size between groups; patients transferred from HD were lighter and shorter, but there was no significant difference in body mass index (BMI). As expected, at the beginning of PD therapy group 2 had a significantly lower urine output. At baseline, both total and residual renal Kt/V and total and residual renal weekly creatinine clearance (CCl) were significantly lower in group 2. These patients had significantly higher peritoneal clearances (Figure 1) . At the start, group 2 had also significantly higher haemoglobin level; this difference disappeared 3 months from the beginning of peritoneal dialysis (data not shown). Peritonitis rate was significantly higher in patients transferred from HD in comparison to patients on primary PD therapy (0.86 versus 0.62 episode/year, P < 0.05).
Survival analysis
Cumulative observation was over 7900 patient-months and median observation period was 20.5 months (range 1-132 months). During the time of observation, 71 patients died, in 100 patients kidney transplantation was performed, 56 were transferred to HD and renal function recovered in 5, allowing for independence from renal replacement therapy. Thirty-two patients were still on PD at the end of the study. The overall patient survival at 1 year was 92.4%, at 3 years There was no significant difference in unadjusted survival between patients with primary PD therapy and those transferred from HD.
There was no difference in unadjusted patient survival between the two study groups (Figure 2 ). Technique survival was significantly lower in patients transferred from HD (P < 0.05) (Figure 3) . Survival of patients older than 60 years at the start of PD, but not technique survival, was significantly lower than in the younger patients (P = <0.0001 and P = 0.19, respectively).
In Cox multiple regression survival analysis, therapy with PD as a primary or secondary modality (group 1 or 2) was included into the model together with age, gender, diabetic status, BMI, diuresis, serum albumin, serum phosphate and haemoglobin level. In this model, only older age, presence of diabetes and low albumin level significantly and negatively influenced patient survival. There was no significant difference in survival between the groups, when adjusted for these factors ( Table 2) . None of the included variables influenced technique survival significantly. In the combined patient and technique survival model, only age and diabetes status were found as significant factors, while serum albumin level was borderline significant (Table 2) .
Unadjusted survival in 67 patients transferred from haemodialysis was not influenced by the cause for which they had changed their dialysis modality (data not shown). 
Discussion
Randomized trials in dialysis are very difficult to perform, and the assessment of patient survival depends on observational studies and registry data [12] . As populations treated with the different modalities may not be similar with respect to case-mix and comorbidities, it is important to adjust for these differences [13, 14] . These studies usually give attention to comparison of survival between dialysis methods; however, as many patients change modalities during their dialysis treatment, it is important to evaluate the effect of these transfers. It is well recognized that technique survival remains unsatisfactory in PD, and many patients change to HD predominantly due to complications. Among them, peritonitis and deterioration of peritoneal membrane function with loss of ultrafiltration remain the most common causes [3] [4] [5] 8, 15, 16] . In some PD programmes, a planned transfer to HD is considered when patient looses residual renal function or as a scheduled prevention measure against peritoneal sclerosis. Technique failure in HD is far less common; however, as haemodialysis is much more prevalent than PD, a substantial percentage of PD patients had been treated with HD before entering the peritoneal dialysis programme [3, 7, 8] . The main reasons for such transfers are vascular access problems or complications experienced during HD like intra-or postdialytic hypotension related predominantly to fluid loss during procedure and aggravated by heart failure or cardiovascular neuropathy [8, 17, 18] . Heparin-induced thrombocytopaenia is a less common complication resulting in transfer to PD, and finally some patients are transferred due to their preference [17, 18] . In this single centre observational study, we have analysed and compared therapy outcomes in two groups of patients. In our unit, PD was the primary therapy for the majority of patients (group 1). For the remaining 25% of our patients, PD was a secondary therapy after they had been treated with HD for a various length of time (group 2). The relatively high percentage of patients transferred from HD was probably due to the fact that when our centre started the PD programme in 1993, it was the only one in a large area of northern Poland. Many patients with long-standing complications in HD, predominantly vascular access problems, were transferred in the early years, when this option had become available. However, it is not surprising, as among patients treated with PD, similar percentages of patients coming from HD have also been reported in the USA [3] and slightly lower in Denmark and Poland [7] .
The two study groups differ substantially. There are significantly more females in the patients transferred from HD. This is not unexpected, as females have more complications with vascular access for HD. In this respect, the DOPPS study found females in the USA and Europe significantly less likely to use native fistula or permanent dialysis access [19] . There was also a significant difference in body size between the groups. The group 2 patients had significantly lower weight and height. Most probably these differences were also due to the higher percentage of females in this group. However, there was no difference in BMI that was in the normal range. Group 2 also had significantly less patients with diabetes. As the mortality rate of diabetics is significantly higher and median time on HD before the transfer was considerably long, this was probably related to the fact that diabetic patients had less chance to survive up to the time of the transfer than nondiabetics. Obviously, patients transferred from HD were more likely to be anuric; as a result they had also significantly lower residual renal Kt/V and creatinine clearance. Despite higher peritoneal clearances in this group, both total Kt/V and CCl were lower in patients transferred from HD. The initial haemoglobin level at the start of PD therapy was significantly lower in group 1. This difference was due to the fact that many chronic kidney failure patients were not given erythropoietin (EPO) while pre-dialysis (especially in the early years of the PD programme), while at the same time, most patients on HD were treated with EPO. This difference disappeared later during the PD therapy and EPO administration.
There was no difference in unadjusted survival between the two groups. In the Cox proportional hazard model, as it could be expected, patient age, diabetes status and albumin level significantly influenced patient survival. However, the relative risk of death was not significantly higher in patients who had been transferred from HD. In most other papers that assessed survival between similar groups, there was a small but statistically significant difference in patient survival [3, 7, 17, 18] . It has to be taken into account that patients who are transferred between modalities due to problems and complications are often negatively 'selected' and are predisposed for inferior survival, irrespective of the direction of transfer [7] . However, the selection may also be positive, as many fragile patients might had not survived to the point of transfer, leaving the more 'healthy' population. It is possible that, as in our study, the median time spent on HD was rather long (18 months); many patients with comorbidities might had died during that time. Additionally, among our patients, in contrast to other similar studies, a much higher percentage was transferred due to vascular access problems, while in most other studies, heart failure was the most common reason for transfer. As this complication is related to increased mortality, these differences may explain, at least in part, the discrepancies between our results and the others. Interestingly, the unadjusted technique survival was significantly lower in the group of patients transferred from HD. This finding was most probably related to significantly higher peritonitis rate and lower urine output in this group. Similarly, technique survival was lower in patients transferred from HD in the report from the USA, where patients were transferred back to HD predominantly due to infection, catheter and adequacy problems [3] . The relationship between peritonitis rate and technique failure is a simple and direct one. Additionally, anuric patients are more likely to develop dialysis adequacy problems, especially related to volume status and overhydration, which may result in their dropout. It appears that these two issues need to be addressed, especially in this group of patients. Firstly, for many of these patients, PD was not a preferred method and probably some of these patients were not the best candidates for PD. Therefore, it is important to implement a detailed and systematic patient training programme in this group. Secondly, special care should be taken to reach adequate dialysis, especially with respect to fluid status assessment and management. It may be difficult in some patients; however, excellent results can be achieved in anuric patients, both in CAPD [20] and APD [21] . In this respect, it is of note that at the start of our study, patients transferred from HD had significantly higher peritoneal clearances. It appears that to achieve adequate small solute clearance and proper fluid balance, many of these anuric patients may need continuous automated dialysis and use of icodextrin to increase ultrafiltration.
In conclusion, our data suggest that the outcome of patients transferred from HD may be similar to that achieved in patients in whom PD is the first choice therapy. Thus, this option should be strongly considered in patients experiencing complications on HD, mainly vascular access problems, heart failure and intradialytic hypotension.
Introduction
Peritoneal transport characteristics play an important role in determining morbidity, mortality and management of peritoneal dialysis (PD) patients. Small solute peritoneal membrane transport is assessed by the peritoneal equilibration test (PET) [1] . Membrane peritoneal transport varies between patients and can change over time in the same patient [2] [3] [4] [5] [6] [7] [8] [9] .
Patients with high small solute membrane peritoneal transport have an increased risk of morbidity and mortality, in spite of their more rapid diffusive clearance of urea and creatinine [10] [11] [12] . However, in patients with high small solute membrane peritoneal transport, the increased risk of mortality could be mitigated by the optimization of the short dwell lengths using automated peritoneal dialysis (APD), combined with icodextrin, rather than continuous ambulatory peritoneal dialysis (CAPD) [12] .
Ascertaining patients' peritoneal membrane transport status early on during the PD training would, therefore, be highly advantageous to determine their optimal PD prescription at the start of PD therapy. However, a retrospective study [13] and a prospective study [14] showed that peritoneal membrane transport increased during the first weeks of PD therapy. Based on these studies, current clinical guidelines [15] [16] [17] recommend caution against performing PETs in the first month of PD commencement.
At the moment, there are no studies about the changes of peritoneal membrane transport before and after the start of PD. Furthermore, there are no studies about the influence of PD prescription at the start of PD on the peritoneal membrane transport.
